Modality
Bispecific Ab
MOA
GLP-1/GIP
Target
Tau
Pathway
RAS/MAPK
Wet AMD
Development Pipeline
Preclinical
~Jan 2021
→ ~Apr 2022
Phase 1
~Jul 2022
→ ~Oct 2023
Phase 2
Jan 2024
→ Oct 2028
Phase 2Current
NCT05414436
2,120 pts·Wet AMD
2025-09→2026-06·Terminated
NCT05167480
1,457 pts·Wet AMD
2024-01→2028-10·Active
3,577 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-06-132mo awayPh3 Readout· Wet AMD
2028-10-212.6y awayPh3 Readout· Wet AMD
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P2/3
Active
P2/3
Termina…
Catalysts
Ph3 Readout
2026-06-13 · 2mo away
Wet AMD
Ph3 Readout
2028-10-21 · 2.6y away
Wet AMD
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05414436 | Phase 2/3 | Wet AMD | Terminated | 2120 | BodyWt |
| NCT05167480 | Phase 2/3 | Wet AMD | Active | 1457 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| BEA-4274 | Beam | Phase 1/2 | ALK | |
| PST-2276 | Poseida | Approved | Aβ | |
| Adagrafutibatinib | Astellas | Phase 2 | CDK4/6 |